Karyopharm to sell itself in bankruptcy and merge with Ayrmid

· Health · United States

Karyopharm Therapeutics, a commercial-stage blood cancer biotech that makes a multiple myeloma drug, plans to sell itself through a court-supervised bankruptcy auction and merge with Ayrmid, Endpoints News and BioPharma Dive report. Ayrmid is the company that previously tried to buy bluebird bio, according to Endpoints. BioPharma Dive reports that the parent of cell therapy maker Gamida Cell will be the lead bidder in the auction, and that Karyopharm recently struck a forbearance deal to postpone debt payments as it ran short of options. The filings mark a difficult turn for a company that had reached the market with an approved product. The process will determine recoveries for creditors and the future of the myeloma franchise.

Why it matters：A marketed-product biotech resorting to a bankruptcy auction illustrates how debt-heavy balance sheets are forcing consolidation among small commercial drugmakers, with implications for creditors and patients relying on its therapies.

Key points

  • Karyopharm makes a multiple myeloma drug and had reached commercial stage.
  • The Gamida Cell parent will be lead bidder in the court-supervised auction, per BioPharma Dive.
  • Ayrmid previously tried to buy bluebird bio.

Sources (original reporting)

More stories from this day